OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-03-31-accounts

The Haemophilia Society Annual Report 2024125 The Haemophilia Society

The Haemophilia Society

Annual Report 24/25

About the Haemophilia Society

We are the only UK-wide charity for everyone affected by a genetic and acquired bleeding disorder, and our charity is here for you.

At the Haemophilia Society (THS) we want to empower everyone affected by a bleeding disorder to live life to the full, whatever your stage in life.

One in 2,000 men, women and children in the UK have a diagnosed bleeding disorder, which are a group of conditions, including haemophilia and von Willebrand disorder, that result when the blood cannot clot properly.

As many as a third of bleeding disorder diagnoses have no known family history and can be the result of a random gene mutation. This means a bleeding disorder diagnosis can come completely out of the blue.

THS brings together people with bleeding disorders and their families to share experiences and understand more about how to live well with a bleeding disorder. Together, we can all make a difference.

----- Start of picture text -----
Contents
3 Welcome from our Chair 36 Trustees' report
4 Our year in numbers 39 Independent auditor's report
6 Who we are 43 Statement of financial activities
8 What we do (including income and
27 How we use your money expenditure account)
28 Fundraising and partnerships 45 Balance sheet
30 A big thank you 46 Statement of cash flows
31 Our staff 47 Notes to the financial
33 Our governance statements
----- End of picture text -----

Chair’s welcome

We continue to offer highly valued in-person events to support our entire community, whether it’s families with a child recently diagnosed with a bleeding disorder, young people having a first taste of independence at our summer Youth Camp or our annual Big-Get Together conference which connects and empowers our members, young and old.

----- Start of picture text -----
Conan McIlwrath, THS Chair
----- End of picture text -----

I will start this, my first annual report, on a personal note which I hope captures the pride I have at being the new chair of the Haemophilia Society (THS). I’ve been a member of this wonderful organisation since I was a young boy, thanks to my parents who were heavily involved in THS’s work in Northern Ireland. Had someone told me 10 years ago that today I would be putting my thoughts on a page as chair I would have laughed in disbelief. However, life is full of surprises, struggles, joy and opportunities, and when this chance came around I wanted to grab it. It is an honour to serve as your chair. Whatever your bleeding disorder and wherever you live in the UK, we are here for you and your family.

I’m proud of the work we’re doing to ensure that everyone with a bleeding disorder is supported by THS. We have working groups which focus on rare bleeding disorders and von Willebrand disorder (VWD) to make sure our charity is inclusive and reflects the needs of our whole membership.

Funding our small charity is a serious and increasing challenge and we are so grateful to everyone who has donated, organised a fundraiser or remembered us in their will. We hope the government will honour a recommendation from the Infected Blood Inquiry that our charity should receive statutory funding for our advocacy work. We continue to look for new funding sources and opportunities.

The publication of the Infected Blood Inquiry’s landmark report in May 2024 represented the culmination of decades of support and advocacy from THS on behalf of our members who were infected and affected by the contaminated blood scandal. The result of its six-year investigation was a vindication of the worst fears of the infected blood community and resulted in an apology from the Prime Minister on behalf of the nation. Our work does not stop, in fact it has increased dramatically as we support our members and their families through a complex compensation process.

I look forward to five positive and busy years as chair as we restructure, regroup and focus on delivering what is important for you all.

Conan McIlwrath THS Chair

3

2

The Haemophilia Society

Annual Report 24/25

Stronger 2,153 Our year together items bought in numbers from the shop 8 grants 5430 444 London members marathon event 6.8% increase 14 attendees runners raised £35,577

£284,415 raised through individual giving 152,573 website visitors

13,806 social media 13,446 followers video views

5

4

The Haemophilia Society

Annual Report 24/25

----- Start of picture text -----
Who
we are
Resilient Empowering Compassionate
----- End of picture text -----

Our vision

‘Our new three-year strategy is an ambitious but achievable roadmap which will keep us focused on our key priorities, ensuring that we’re working efficiently and effectively for our members.’

Kate Burt, Chief Executive of the Haemophilia Society

This year we’ve launched a three-year strategy which gives us a clear direction for our future work. We have created a shared mission which we believe will support and empower our members whilst ensuring the ongoing financial viability of our small charity. Kate Burt, Chief Executive

Our four strategic pillars are:

We exist to support you, and everybody affected by a genetic bleeding disorder in the UK, to enable you to live life well. We are both a charity and a member organisation, founded 75 years ago.

The Haemophilia Society supports the bleeding disorders community by:

Today we have 5,430 members, and a very active community on our social media channels. Our posts have a reach of more than 13,000 people.

Making sure that our charity has a sustainable financial footing is a key objective. In the current challenging economic climate it is crucial that THS has firm foundations so that our members can be confident of our ongoing support. We have a new fundraising plan to achieve this by diversifying our major donor sources and encouraging more members to commit to regular giving. We are also calling on government to honour the Infected Blood Inquiry’s recommendation that our charity should receive statutory funding for our advocacy work.

We will continue to use our insight and knowledge to inform health policy, and inform care commissioners. Our aim is always to improve standards of treatment and help to ensure equal access to excellent care for everyone with a bleeding disorder.

We recognise the importance of bringing together our community both online and in-person to share experiences and to reduce isolation and anxiety. Although the cost of hosting events is an increasing challenge, we understand how much our members value the chance to get together and we will do all we can to maintain this service.

Shared stories, knowledge and informed support give people with bleeding disorders and their families the power and confidence to advocate for the best treatment and care.

Our new strategy helps us focus on this all-important goal.

7

6

The Haemophilia Society

Annual Report 24/25

What we do

Youth support

----- Start of picture text -----
Ryan Reynolds, Young Ambassaador
----- End of picture text -----

‘I became a Young Ambassador because I know first-hand what a struggle it can be as a young person growing up with a bleeding disorder and I wanted to help. I loved volunteering at Youth Camp and seeing a change in mindset in the children who left the event believing they could do so much more than when they arrived.’

Young Ambassador Ryan Reynolds, who has severe haemophilia A

Ensuring that our young members are welcomed, supported and empowered to manage their bleeding disorder independently is an important part of our work.

----- Start of picture text -----
Young Ambassador training weekend
----- End of picture text -----

We have a strong Young Ambassador programme, dating back to 2015, which is open to members aged 18-30. Our Young Ambassadors act as mentors to our younger members, offering advice and reassurance about the reality of living with a bleeding disorder. They also attend our events to talk about their lived experience. Many people, particularly parents of newly diagnosed children, find it very reassuring to hear about the full lives these approachable and positive young people lead.

Our Young Ambassadors also regularly attend global conferences to share their experiences, helping them to build their skills to become advocates for themselves and our community.

This year we welcomed three new Young Ambassadors and said farewell to three of our more senior members, who have been wonderful role models for our charity. We held a specialist training session in London in September to boost all our Young Ambassadors’ storytelling skills and to discuss our new strategy to ensure their views were incorporated.

It’s been a year of challenges, with four experienced Young Ambassadors, who all live with bleeding disorders, taking part in tough physical tests. The team tackled the gruelling Fan Dance walk in the Brecon Beacons and, as part of our on-going twinning project, took part in a 6km open water swim between Gozo and Malta. With careful planning in consultation with their medical teams, they completed both events. Two videos will be released in 2025 as a record of their achievements which we hope will inspire other young people with bleeding disorders to take on challenging projects of their own.

----- Start of picture text -----
Team THS at the Gozo-Malta swim
----- End of picture text -----

----- Start of picture text -----
Young Ambassador training weekend
----- End of picture text -----

‘The Malta Swim Challenge summarised why we all do what we do – it proved to others, and more importantly to ourselves, that our bleeding disorders aren’t barriers, and that overcoming the physical and mental challenges often takes a village, which is exactly what we had around us. Completing the challenge alongside friends and family without bleeding disorders also highlighted the importance of a supportive community.’

----- Start of picture text -----
Peta Dixon, Young Ambassador
----- End of picture text -----

Young Ambassador Peta Dixon who has a bleeding disorder of unknown cause (BDUC)

9

8

The Haemophilia Society

Annual Report 24/25

Youth Camp

‘Youth Camp gave my son more confidence in understanding his condition and he enjoyed meeting other children who are managing the same feelings and emotions as him. He and his brother loved the opportunity of trying new activities and conquering some fears too. Thank you!’

Our annual Youth Camp, which is free to members, took place in Staffordshire in July and was attended by 42 young people aged nine to 15 who either have a bleeding disorder or have a sibling with a bleeding disorder. Supporting the families of people with a bleeding disorder is an essential part of our work, and a recognition of the impact that living with a bleeding disorder has on parents, grandparents and siblings.

Bernadette, mum of Ayden and Lucca, who has severe haemophilia A

The camps, which could not be run without the support of our volunteers, including clinicians such as specialist paediatric nurses and physiotherapists, allow our young people freedom and independence in a safe environment. Here they can try activities such as climbing and a high ropes course which builds their confidence.

They also meet others who have been through similar experiences, often resulting in long-lasting friendships. For many of our campers this is the first opportunity they’ve had to stay away from home independently , and gives parents a rare break too.

We were delighted to be joined by a family from Malta, as part of our twinning project with the Malta Bleeding Disorders Society. We hope to support our friends and colleagues in Malta to organise a similar event for young people in the future.

As always, our feedback was excellent from Youth Camp 2024, from both the young people themselves and their parents or carers.

----- Start of picture text -----
Imaan, aged nine
----- End of picture text -----

My daughter loved Youth Camp, she gained a lot of confidence and felt great doing all the activities knowing she is safe and under great guidance. She made lovely friends who she is still in contact with – they are hoping to meet at the next camp.’ Sidra, mum of Imaan, who has Glanzmann thrombasthenia

----- Start of picture text -----
11
----- End of picture text -----

10

The Haemophilia Society

Annual Report 24/25

Community support

Bringing people together to share experiences and find out about the latest care and treatment available is one of the most rewarding aspects of our work. Genetic bleeding disorders are rare, and it can be isolating to be the only person with this condition in a workplace, village, school or sports team. By connecting our members through in-person events and our supportive social media community, people can be reassured that they are not alone in whatever challenges they are facing. Sharing experiences also empowers people to think again about their care as they learn about the treatment of others and find out more about the options open to them.

This year, 444 adults and children registered to attend one of five in-person events held in four locations in England.

Big Get-Together annual conference and AGM

‘I have an extremely rare bleeding disorder. At the Big Get-Together I was able to meet with other people with different rare bleeding disorders, this gave me a safe place to talk about our shared experiences without being judged or dismissed. I feel that I have gained a voice to be able to advocate for myself, my daughter and others. Most importantly, for the first time in my life I have gained a group of friends who understand the issues of living with a rare bleeding disorder as a woman and are now my support network.’

Chris

Our one-day Big Get-Together (BGT) conference and AGM was packed with informative talks, workshops and discussions featuring contributions from some of the UK’s leading experts in bleeding disorder care as well as people who live with a bleeding disorder. Held in Leicester, the event attracted 191 people. Our younger members joined a dedicated teen session run by a specialist paediatric nurse to discuss the issues around living with a bleeding disorder that mattered to them.

In addition to sessions on mental and physical health, we were joined by the interim Chief Executive of the Infected Blood Compensation Authority who offered one-to-one conversations with members of the contaminated blood community. There was also plenty of time to network informally and share experiences.

Newly diagnosed families weekend

What parents said about the event:

‘I enjoyed meeting other families and the childcare was fantastic. The session content was brilliant. I felt cared for and supported by the Haemophilia Society team.’

‘The weekend showed me that I am not alone, there are other families in the same situation as us. Thanks to the Haemophilia Society, we now have a support network, which is lifechanging.’

‘I enjoyed meeting other families and the childcare was fantastic. The session content was brilliant. I felt cared for and supported by the Haemophilia Society team.’

Our Newly Diagnosed Weekends (NDWs) provide families with expert advice, invaluable peer support and a safe space to ask questions in the very early stages of diagnosis. THS Young Ambassadors also attend these events, sharing their experiences and bringing positivity to families who may feel uncertain about their child’s future. Specialist clinicians also support us at NDWs, answering a range of questions about treatment and care.

This weekend is free to our members and offers a creche facility. For many parents, this is the first time they’ve left their child with anyone other than another family member. The experience can be a valuable stepping stone in supporting parents with the transition to nursery.

13

12

The Haemophilia Society

Annual Report 24/25

We held our NDW in Milton Keynes this year where we welcomed 21 adults and 20 children. There were discussions about the benefit of physiotherapy for children and a presentation about the role of specialist haemophilia nurses as well as a chance to talk to young adults living with a bleeding disorder.

Feedback from the event was extremely positive, with 100% of parents telling us that attending the weekend had positively affected their view of living with a child with a bleeding disorder. They also felt more empowered to make decisions about their child’s treatment and wellbeing.

Future of bleeding disorder care seminar at the Royal School of Medicine

We were honoured to be invited by Royal School of Medicine to host an afternoon of discussion and shared experiences focussing on the future of bleeding disorder care at its prestigious headquarters in London.

The free event gave us an invaluable opportunity to engage a new audience of healthcare professionals and people interested in rare conditions as well as involving our members and supporters in top level debate.

Thanks to the support of leading bleeding disorder clinicians and people with lived experience of a bleeding disorder, the event offered a stimulating window into what the future of bleeding disorder care might look like.

A total of 110 people attended the event, including resident doctors and trainee physiotherapists who had an interest in pursuing haematology as a specialism as well as clinicians from different areas who wanted to understand more about haemophilia and other bleeding disorders.

Von Willebrand Awareness Day

More than 30 adults with von Willebrand disorder (VWD) got together to share experiences and discover more about treatment and care at an event organised by the Royal London Hospital’s Haemophilia Centre team, which we were pleased to support.

The aim of the day was to bring people with VWD together to discuss their experiences of living with the bleeding disorder as well as to involve healthcare professionals who gave updates on treatment, barriers to diagnosis,physiotherapy and the benefits of counselling.

Community support event for the contaminated blood community

More than 60 people attended a support event in London for those infected and affected by the contaminated blood scandal of the 1970s and 80s. The event took place on the eve of the publication of the Infected Blood Inquiry’s report and was designed to offer solidarity and friendship as the infected blood community prepared for one of the most important days in the history of this scandal.

Service of Remembrance and Thanksgiving

We are proud to host this important event every October to remember all those people with inherited bleeding disorders who have died due to their treatment with contaminated blood products. The service is held at St Botolph without Bishopsgate, London, where the Book of Remembrance is kept. This year’s service had an exceptionally high attendance, with some families represented by three generations touched by the contaminated blood scandal. As well as remembering loved ones who have died, the event is also a safe and supportive space to talk to others who have been bereaved and are grieving.

Carol Service

Our annual Carol Service held at St Botolph without Bishopsgate is gaining in popularity due in part to the wonderful singing of the church choir and its location in the heart of the City of London. This paidfor event is increasingly being attended by non-members who work locally, giving us an opportunity to increase awareness about our work to a different audience.

Ambassadors

We have three dedicated ambassadors to support our members. These are: THS staff member Scott McLean, our Mental Health Ambassador, William McKeown, our Access and Service Improvement Ambassador and Mark Ward, our LGBTQ Ambassador. All our ambassadors attend conferences on our behalf to highlight and support our work as well as provide us with invaluable insights into the needs of the communities they work with.

15

14

The Haemophilia Society

Annual Report 24/25

----- Start of picture text -----
Mark Ward, THS LGBTQ
Ambassador
----- End of picture text -----

‘I’m incredibly proud to be the Haemophilia Society’s LGBTQ Ambassador. It’s important to me that we have an inclusive and compassionate bleeding disorders community and I’m here as a friend and support to anyone who needs me. I also advocate for the community at conferences, to politicians and a variety of organisations across the UK, because education and understanding about bleeding disorders and the history of our community is essential.’

Mark Ward, THS LGBTQ Ambassador

Working Groups

The Haemophilia Society is committed to supporting all genetic bleeding disorders. We want all our members to have access to services, support and events that match their specific needs and challenges. One way we ensure the needs of those with different disorders are heard and understood is through our working groups. These groups, made up of a diverse group of volunteers, are dedicated to representing, advocating for and serving the needs of a specific community within our membership. This helps us shape what we do to ensure these needs are properly met.

Women’s Working Group

We have 18 members of the Women’s Working Group who represent women with a range of genetic bleeding disorders or who care for a female with a bleeding disorder. The group takes the lead in setting the agenda for our annual Talking Red Live conference which is a day dedicated to women and girls with a bleeding disorder. Through regular online meetings, the group also helps to shape our priorities for this section of our membership. Members have provided valuable contributions to the SACRed project, our latest major research initiative into the treatment and care of women and girls (see Advocacy). The group was formed in 2020.

Rare and Bleeding Disorder of Unknown Cause (BDUC) Working Group

‘I’m the only person in my family with a bleeding disorder and I didn’t know anyone with a bleeding disorder, so it has been great to get to know the other members of the group and follow their journeys. It’s nice to have that community inside the Haemophilia Society. I attended my first conference about rare bleeding disorders thanks to the group, which was really informative. I learnt a lot about what treatment is – and sometimes isn’t – available for rares and it gave me more confidence to advocate for better care.’

Launched in 2024, the Rare and BDUC Working Group has attracted members representing more than eight extremely rare conditions, such as Glanzmann thrombasthenia, factor V deficiency and factor VII deficiency. Although every condition is different, common themes have emerged, such as challenges with diagnosis, treatment, and psychological support. From this, the group has set goals which include identifying educational gaps for healthcare professionals, improving information online and for treating clinicians. The group meets monthly online and has created a much-needed space for individuals to share experiences, promote understanding and create ideas on how to improve knowledge about their conditions.

Von Willebrand Disorder (VWD) Working Group

Established in 2023, the VWD Working Group was set up to raise the profile of this condition within the bleeding disorder community, healthcare profession and the general public.

There are about 11,500 people in the UK with a VWD diagnosis, which makes it the most common genetic bleeding disorder. Despite this, it is a condition that can take years to diagnose and one about which most people know very little. Our VWD Working Group aims to change this.

Publications

Lucy, who has a factor VII deficiency and is a member of the Rare and BDUC Working Group 16

17

The Haemophilia Society

This year we produced 12 booklets and 19 downloadable factsheets. We sent out 1,501 publications, some of which are available in five languages, including Welsh, Urdu and Arabic. The booklets are used in haemophilia centres as well as by individual members to help them and their friends and relatives to understand their condition.

This year we offered the following free publications:

We offered the following downloadable factsheets:

----- Start of picture text -----
Annual Report 24/25
rts D
S o a
p y
----- End of picture text -----

Video projects

This year we launched a video project to encourage children with bleeding disorders to get involved in sport, featuring Chris Clotter, our mascot and young person’s champion.

The series of four short videos offer practical advice and support to parents, emphasising the benefits of getting and keeping their children fit and healthy by ‘Chris Clotter’s Sports finding a sport they love. Day’ animation series

We’re excited that the project is endorsed by two elite athletes who have reached the top of their sports while living with haemophilia. Alex Dowsett, a former professional cyclist and Ed Fuller, who won gold as a rower in the Paralympic Games in Paris in 2024, both feature in the videos as animated characters.

The Sports Day concept is now being taken toward as a UK-wide community event, planned for Autumn 2025.

We will also be releasing videos of the Young Ambassador’s long-distance swimming and walking challenges in the UK and Malta later in 2025 to inspire others to believe that, with the right clinical support, most physical activities are possible.

Infected Blood Inquiry

----- Start of picture text -----
19
----- End of picture text -----

18

The Haemophilia Society

Annual Report 24/25

‘This is a day of shame for the British state…the result of this inquiry should shake our nation to its core.’

‘I’m grateful for the incredible support I had

from the Haemophilia Society who have put so much energy into helping our community through the compensation process. Communication has been helpful and staff have gone out of their way to give me support when I had nowhere else to turn.’

Prime Minister, Rishi Sunak

The contaminated blood scandal has been a central part of our campaigning and support work for the last five decades. In 2017 there was a great leap forward when the government set up the Infected Blood Inquiry to investigate how and why people were infected with viruses including hepatitis C and HIV through contaminated NHS blood and blood products in the 1970s and 80s. More than 3,000 people who were infected have died following their infections, and thousands more lives have been ruined as a result of this scandal.

Meg

In May 2024 the Infected Blood Inquiry, after six years of analysing evidence, published its report which concluded that the scandal could have largely been avoided and was a result of multiple failings across institutions including government and the NHS. Repeatedly, patient safety was not prioritised. The Prime Minister apologised on behalf of the nation and accepted that compensation should be paid. The inquiry’s conclusions attracted global interest and our charity’s representatives were interviewed by national and international media, helping to highlight significance of the issue.

The inquiry’s Recommendations nine and 10 are focussed specifically on bleeding disorder care and advocacy. Recommendation nine outlines measures for protecting the safety of haemophilia care and Recommendation 10 focuses on giving patients a voice. We are active members of various working groups tasked with providing the expertise to enable government to implement the inquiry’s recommendations. (See Advocacy section).

After decades of campaigning by THS and many other groups, it was a major milestone to hear the government commit to setting aside £11.8 billion for a compensation settlement.

Much of our work since this announcement has been lobbying government to produce a fair compensation scheme and to implement the report’s other recommendations. We also received a huge number of calls and emails following the publication of the government’s compensation scheme and have devoted significant staff time to supporting our members through the process.

While progress this year has been significant, it has also been a period of great uncertainty as the infected blood community tried to make sense of what the proposed compensation scheme meant for them. Many fear dying before justice is seen to be done.

Our Public Inquiry Team continues to support those infected and affected by the scandal and keep our members up to date with the work of the Infected Blood Inquiry and any political developments. We hold webinars on key topics and run a dedicated Facebook support page as well as a Twitter/X account for news updates.

We are pleased to be working with the Wellcome Trust on an archiving project which will ensure all the documents stored by THS for use by the inquiry will be preserved. We expect most of this information to be publicly available, although some documents will need to be redacted to ensure personal data is not compromised.

Advocacy and influencing

A vital part of our charity’s work is advocating for higher standards of treatment and care and greater awareness of bleeding disorders. We represent our members across the UK through engagement at all levels from parliament and central government, through health and NHS bodies, clinician groups and other stakeholders all the way down to individual centres, hospitals and trusts.

All Party Parliamentary Group on Haemophilia and Contaminated Blood

Standards of Care and Access to Treatment

We founded the Haemophilia and Bleeding Disorder Alliance, a group that brings together patient groups from across the UK and clinician groups to speak as one voice on issues affecting people with a bleeding disorder and to push for higher standards and better access to treatment and care. With the UK-wide audit of haemophilia centres now complete, the alliance is preparing to consider its finding when they are published later in 2025 and to push for gaps in care to be addressed by the relevant trusts and Integrated Care Boards (ICBs). The alliance is also focused on ensuring that the Infected Blood Inquiry’s recommendations relating to improvements in bleeding disorder care are implemented.

We continue to be a member of the specialised blood disorders Clinical Reference Group (CRG) as one of the two patient representatives on the group. The CRG works with NHS England to coordinate specialist care for people with bleeding disorders and leads on the development of new treatment and care guidelines, policies and service specifications.

A new draft service specification was finalised which will establish an important baseline in bleeding disorder care. It focusses on access to full multidisciplinary care, improving people’s rights to physiotherapy, providing better care to women and girls with bleeding disorders and providing more psycho-social support. This will be consulted on in 2025 and come into force in 2026.

We have also been continuing to press for a bespoke psychological support service for England. As well as campaigning for this service we have also provided advice and insight about how the new service should look. Northern Ireland, Wales and Scotland already have this service, but England lags behind. While progress has been made, the new service is not due to be operational until Summer 2025.

21

20

The Haemophilia Society

Annual Report 24/25

Debra Morgan and Laurence Woollard at the 2024 Labour Party Conference

In response to the Infected Blood Inquiry’s Recommendation nine, NHS England worked with us and other stakeholders to ascertain the size of resource gaps across haemophilia centres. A proposal we worked on to improve funding for centres is now under consideration by the Department of Health and Social Care (DHSC).

We also developed, with NHS England, a proposal to strengthen networks for haemophilia centres so they work more collaboratively to support people with bleeding disorders. We were involved in developing new clinical commissioning policies for recombinant von Willebrand factor and expanded use of the subcutaneous haemophilia A treatment emicizumab.

We continue to work with NICE, a government body which evaluates new treatments for use in the NHS. We support the process by advocating for the needs of patients and demonstrating the need for new treatments. This year we made written and oral submissions to the NICE review of marstacimab a new subcutaneous treatment for haemophilia A and B. In addition, our advocates, including President of the Haemophilia Society, Clive Smith, gave evidence to committees considering a new long-acting factor product for haemophilia A, efanesoctocog alfa. Our previous work on access to gene therapy for haemophilia B paid off, with a positive recommendation for funding for Hemgenix through the Innovative Medicines Fund, which was announced in June 2024. This announcement means that gene therapy is now available on the NHS for people with severe haemophilia B, which is a major treatment breakthrough.

We are members of NHS England’s Specialised Commissioning Stakeholder Forum and the Specialised Health Care Alliance (SHCA) which allows us to raise wider issues about how NHS treatment and care is commissioned and delivered across England. We also work with the Haemophilia Nurses Association (HNA), the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) and the Haemophilia Chartered Physiotherapists’ Association (HCPS) to ensure patient’s views are taken into account in all aspects of haemophilia and bleeding disorder care.

We were part of the DHSC’s Homecare Medicines Services Patient and Professional Advisory group to improve monitoring and outcomes for people who rely on home delivery of treatment.

The SACRed Project, a multiyear investigation into the experiences of women and girls with bleeding disorders was completed this year. The final report, Underserved/Overlooked: How our health systems are failing women and girls with a bleeding disorder will be published in Summer 2025.

We supported Genomics England’s Generations Study, a project to provide genetic testing for rare diseases to newborns, in development of patient information for people with suspected bleeding disorders.

Influencing the political agenda

Through our work in parliament, we seek to ensure that the treatment and care needs of people with genetic bleeding disorders is understood by political decisionmakers of all parties. After the general election in July 2024 we worked with Clive Efford MP to reestablish the All-Party Parliamentary Group (APPG) on Haemophilia and Contaminated Blood. We were reappointed as secretariat of the APPG with responsibility for facilitating meetings, coordinating parliamentary campaigns, updating MPs on developments in bleeding disorder care and treatment, briefing MPs on the campaign for justice for people infected and affected by contaminated blood products and maintaining the webpage, social media and membership information of the APPG.

We attended the Labour Party conference in Liverpool, and had useful conversations with delegates about the future of the NHS and how to ensure that a fair compensation scheme is delivered to people impacted by contaminated blood products.

Global connections

THS values and seeks to strengthen our links with fellow haemophilia and bleeding disorder associations around the world. We believe that our attendance at bleeding disorder conferences is essential in giving us the knowledge and contacts to advocate effectively for our members. These events also offer our Young Ambassadors and our members the chance to find out more about their condition and how to advocate more effectively for better treatment and care.

We attended major global conferences including the European Haemophilia Consortium (EHC) conference in Sofia, Bulgaria and the World Federation of Hemophilia’s (WFH) conference in Madrid, Spain. Amy Owen-Wyard, a THS trustee and our nominee, was elected to join the EHC’s steering committee.

Amy Owen-Wyard at 2024 EHC conference in Sofia, Bulgaria

23

22

The Haemophilia Society

Annual Report 24/25

We also had a representative at the EHC’s New Technologies conference in Helsinki in Finland where the latest treatment and research is unveiled and discussed. We also sent two staff members to the European Association for Haemophilia and Associated Disorders (EAHAD) conference in Milan, Italy. Members of our Rare and Bleeding Disorder of Unknown Cause Working Group attended the EHC’s European Rare and Inhibitor Network Summit in Zagreb, Croatia and we sent representatives to the EHC’s Leadership Development Conference in Brussels.

We were also pleased to be invited to attend the National Institute for Health and Care Excellence (NICE) in Manchester, England. Our Chief Executive, Kate Burt, addressed the annual conference of the haemophilia doctors’ organisation, the UKHCDO in London, England.

In addition, we have individual members who are active on the international stage. Our member, Bonnie Taylor, who has severe haemophilia A, is the EHC’s Ambassador for Women with a Bleeding Disorder. Our trustee Jo Traunter is a member of the EHC’s von Willebrand disorder (VWD) Working Group and Amy Owen-Wyard is chair of the EHC’s European Rare and Inhibitor Network (ERIN).

Malta twinning project

Our four-year twinning project with the Malta Bleeding Disorders Society (MBDS), funded by grants from the World Federation of Hemophilia is now in its second year. We are working with the MBDS board to improve their governance, increase their fundraising capacity, strengthen their advocacy and get better access to care and treatment in Malta.

----- Start of picture text -----
THS staff and ambassadors at a work-
shop with the Malta Bleeding Disorders
Society
----- End of picture text -----

This year, we welcomed a family from Malta to the UK attend our Youth Camp, which we hope will inspire a similar event in the future. A delegation of staff, Young Ambassadors and trustees travelled to Malta in September 2024 for a weekend of workshops and advocacy, culminating in some of the team undertaking the Gozo to Malta open water swim to raise money for a youth support event in the country. We really value the strengthening ties that are developing between our two organisations.

----- Start of picture text -----
Amy Owen-Wyard and Mark Ward visiting 24
haemophilia centra at Mater Dei in Malta
----- End of picture text -----

Working together across the UK

National haemophilia centres

We are grateful for the productive relationships we have with the national haemophilia charities in Wales, Scotland and Northern Ireland. We liaise with both all organisations to maximise advocacy, particularly in relation to issues arising from the Infected Blood Inquiry’s work.

Little Bleeders

We continue to work closely with Little Bleeders, the charity established by former professional cyclist Alex Dowsett, which encourages young people with bleeding disorders to get involved in sport and stay active

Our volunteers

‘I find it rewarding to be able to provide lived experience as a trustee. Ensuring that THS’s priorities are shaped by the dayto-day experiences of people living with a bleeding disorder is very important to me.’ Rayaz Chel, THS trustee THS trustee Rayaz Chel (right) with Dr Gary Benson

----- Start of picture text -----
THS trustees at a board meeting
----- End of picture text -----

----- Start of picture text -----
25
----- End of picture text -----

The Haemophilia Society

Annual Report 24/25

----- Start of picture text -----
THS staff member, Rosie
Devlin volunteering at Youth Camp
----- End of picture text -----

----- Start of picture text -----
THS staff member, Julia Collins, and Young
Ambassador, Ryan Reynolds volunteering
at Youth Camp
----- End of picture text -----

Without our volunteers, we would be unable to host the events which we know our members find so valuable, nor could we run our charity, which is governed by unpaid volunteers who are elected to serve on our Board of Trustees. We’d like to thank our trustees, who give their time so generously to ensure our organisation is run as efficiently and productively as possible for the benefit of our members.

We are very grateful to our clinical volunteers, such as haemophilia nurses, consultants and physiotherapists, who give up their time to attend events, such as Youth Camp and Newly Diagnosed Weekends, or to speak at our conferences or information days. We also could not manage events such as Youth Camp without an army of volunteers to oversee the welfare of those attending, as they climbi walls, canoe, zip-wire and other fun activities that make this event so special for our younger members. We appreciate the contribution of every single volunteer.

How we use your money

----- Start of picture text -----
11.9%
----- End of picture text -----

21.6%

45.5%

21%

THS trustee, Natalie Lawson and Michael Warwick volunteering at Youth Camp

Fundraising

Campaigns and communications

Membership and services

Public inquiry

27

26

The Haemophilia Society

Annual Report 24/25

Fundraising and Partnerships

Development of Chris Clotter videos - SOBI, Roche-Chugai

Policy programmes

Sacred Project on-going research - SOBI, Roche-Chugai, LFB, Octapharma, Takeda

Dental Survey Publication of Findings - Nordic

Publications

Development of Ageing booklets - Octapharma

Development of Paediatric Dental Booklets - Nordic

Review of Understanding Haemophilia and Schools Booklets - SOBI

We are grateful to have such dedicated partners who help us to support our members and the wider bleeding disorders community. The generosity of charitable trusts, corporate partners and volunteers helps us to continue to deliver our core services for our members.

Corporate partners

We receive ongoing support from partners in the pharmaceutical and private sectors, which includes sponsorship of member events, charitable grants and travel expenses to educational events.

Without this funding, it would be impossible for us to run many of our events which offer essential support to our members. We would like to emphasise that there are strict guidelines relating to donations from pharmaceutical companies to health organisations which we adhere to at all times.

Companies must respect the independence of the project and organisation to which they have donated and are not allowed to influence any of its written material. As per clause 29 of the 2021 ABPI code, all pharmaceutical companies must declare their sponsorship of ‘patient organisations’, which is how THS is classed under the code.

This year we are grateful for support from our corporate partners in the following areas of our work:

Events

Young Ambassador’s training day, London, September 2024 - SOBI

Youth Camp, Whitemoor Lakes, Staffordshire July 2024 - Takeda, Roche-Chugai, EHC

Big Get-Together annual conference, Leicester, Nov 2024 - SOBI, Takeda, LFB, Pfizer

Newly Diagnosed Weekend, Milton Keynes, May 2024 - SOBI, Novo Nordisk, Roche-Chugai, Pfizer, LFB

Digital projects

Attendance at conferences

WFH Madrid, April 2024 - SOBI, Roche- Chugai

EAHAD, Milan, Feb 25 - LFB

Royal Society of Medicine supported:

Medicines and Me event, London, February 2025

European Haemophilia Consortium supported :

Attendance at Conference:

New Technologies in Bleeding Disorders, Helsinki, Nov 24

EHC Leadership Development Conference June 24

ERIN Conference December 2024

Events:

Youth Camp 2024

Came from core funding:

EHC conference in Sofia, October 24

Labour conference in Liverpool, September 24

Service of Remembrance and Thanksgiving October 2024

Young Ambassador’s Fan Dance Walk and video project - SOBI, CSL Behring

Young Ambassador’s Malta to Gozo swim and video project - Pfizer

29

28

The Haemophilia Society

Annual Report 24/25

Trusts and Foundations

We continue to strengthen our relationships and grow support from trusts and foundations to fund our ongoing project delivery. We have built robust sources of funding and are committed to further strengthening our partnership with our funders to support continued growth.

Thank you to the following trusts and foundations for your support this year:

Adint Charitable Trust, The Astor Foundation, Harris Charitable Trust, Douglas Heath Eve Charitable Trust, Sir Samuel Scott of Yews Trust and Hospital Saturday Fund.

A big thank you

Thank you to everyone who walked, ran, cycled, swam, sky dived, played golf, baked, organised raffles and undertook many other challenges to raise funds for THS. We appreciate all that you do for our charity.

We have some of the most loyal and generous supporters any charity could wish for. The individual donations and legacies that we receive and the contributions from our partners, large or small, makes everything that we do possible.

Our

Fiona Donoghue HR and Office Manager

Kate Burt Chief Executive

Debra Morgan Head of Policy and Campaigns

Together, we continue to work to improve the lives of everyone with a genetic bleeding disorder and their families in the UK.

----- Start of picture text -----
Georgia, and Reggie, after
completing the Colchester
Zoo run
----- End of picture text -----

----- Start of picture text -----
Ross running the
2024 London Marathon
----- End of picture text -----

----- Start of picture text -----
Barry doing a
wing walk in memory of his
wife
Emily and Heather after
finishing the London -
Essex bike ride
30
----- End of picture text -----

----- Start of picture text -----
Nicola Sugg
Events and Membership Manager
----- End of picture text -----

Julia Collins Events and Content Officer (until August 24)

31

The Haemophilia Society

Annual Report 24/25

Jessica Bomford Communications Manager Jefferson Courtney Policy and Public Affairs Manager

----- Start of picture text -----
Scott McLean
Fundraiser and Member Advocate
----- End of picture text -----

Rosie Devlin Trusts and Data Officer

Sam Wilson Digital Marketing and Content Manager

Paula McCabe Finance Officer (until December 24)

Our governance

We work hard to set the highest standards as an organisation. Our policies and procedures reflect our values and we designed them to help us keep to those standards. We communicate them to our employees and volunteers and give everyone the training they need to uphold them. We also record our decisions and incidents, monitor our performance, and gather feedback to help us learn and improve.

This year we updated our Articles of Association, the document which defines our governance and purpose, to better reflect our work as a modern charity. The changes were approved at an Emergency General Meeting in October 2024.

We are signed up to the Fundraising Regulator’s ‘Fundraising Promise’ which summarises our commitment to individuals who support our work. The promise includes a commitment to make our supporters’ experience as positive and rewarding as we can. We are committed to being honest and transparent about where our supporters’ donations go and why we need funding. The safety of our supporters’ data is very important to us.

We are determined to take all obligations seriously and we will:

33

32

The Haemophilia Society

Annual Report 24/25

Administration and legal details

President Baroness Meacher (until November 24), Clive Smith (from November 24) Medical and Scientifc
Advisory Group		 Dr Rezan Abdul-Kadir
Patrons Baroness Meacher, Dame Diana Johnson MP and Kate Khair (from November 24) Dr Susie Shapiro
Chief Executive Kate Burt Anna Wells
Cathy Harrison
Board of Trustees Clive Smith - Chair (until November 2024) Dr Gary Benson
Conan McIlwrath - Chair (from November 2024) Dr Lochana Nanayakkara
Susan Stretch - Vice Chair (resigned January 2025) Dr Mary Mathias
Gordon Dixon - Treasurer Dr Suthesh Sivapalaratnam
Simon Blackwell (co-opted January 2025) Natalie Lawson
Paul Sartain
Joanne Traunter Company Secretary Paul Sartain
Natalie Lawson
Helen Tate (elected November 2024) Bankers Natwest Bank
Amy Owen-Wyard - Vice Chair (from December 2024) London Bridge
Rayaz Chel - Vice Chair (from December 2024) PO Box 35
Lisa Bagley 10 Southwark Street
Stacey McGeown London, SE1 1TJ
Peta Dixon (co-opted November 2024)
Solicitors Eversheds Sutherland
Subcommittees 1 Wood Street
London, EC2V 7WS
Finance and Risk Committee
Gordon Dixon - Chair Auditors Ellacotts Audit Service Limited
Clive Smith Countrywide House
Conan McIlwrath 23 West Bar
Susan Stretch (until January 2025) Banbury, OX16 9SA
Rayaz Chel
Company registration number 01763614
Nominations Committee Gordon Dixon
Clive Smith (until November 2024) Charity registration number 288260
Public inquiry Committee Clive Smith - Chair (until November 2024)
Conan McIlwrath (from November 2024)		 Scottish charity registration number 288260
Susan Stretch (until January 2025)
Paul Sartain
Eileen Ross
Barry Flynn

35

34

The Haemophilia Society

Annual Report 24/25

Reserves

THS held investments at 31/03/2025 of £351,614 .

Trustees’ report

The Trustees present their annual report and financial statements for the year ended 31 March 2025.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity’s governing document, the Companies Act 2006, FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” and the Charities SORP “Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)”.

In recognition of the significant financial and general resource impact of the ongoing Infected Blood Inquiry, THS has invested £1,033,000 of the charity’s reserves on our work supporting the inquiry and the infected blood community since 2017. Even with this level of investment we have not been able to keep up with demand for our support, particularly over the last 12 months as our supporters have tried to work out what the Infected Blood Compensation Scheme means for them.

Under the Memorandum and Articles of Association the trustees may invest surplus funds in any investment they consider appropriate. To this end we have invested in COIF Investment Funds, which invest on our behalf, based on a diversified and prudent investment strategy directly into assets to mitigate concentration of risks.

Reserves policy

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month’s expenditure. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity’s current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

Objectives and activities

Public benefit

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

Achievements and performance

Significant activities and achievements against objective s

Financial review

The unpredictable and challenging times the charity and voluntary sector has experienced in recent years continued in the financial year 2024-2025. For THS, as for many organisations, the 'perfect storm' created by funding falling, costs increasing, and demand for our support climbing remains. These challenges make it more important than ever that we focus on efficiency and ensuring that we offer our members a relevant and useful service with an increased effort on achieving diverse and reliable funding sources.

Income for FY25 grew by 7.2% compared to FY24 to £590,300. However, corporate and events income fell short of forecast and has still not returned as we had projected to pre-pandemic levels. Costs were reduced by 8.5% for FY25 with total expenditure of £862,700. Overall, we have generated a loss for the year of £277k, which resulted in a significant reduction of reserves.

Legacy income received of £85,680 FY25 decreased by 53% compared with the previous year and by 89% from FY23. Given the nature of legacies, there will always be a large variance on a yearly basis. We are grateful to all our members who remember THS in their will.

Key risks and uncertainties

Key risks to the charity fell into two distinct areas and were identified as:

Financial

As described above, we are operating in a challenging financial environment and planning to focus our income generating strategy on building trust and foundation relationships as well as increasing and diversifying our corporate partnerships. The Infected Blood Inquiry report published in May 2024 including a recommendation that THS receives statutory funding to support our advocacy work and giving patients a voice. Negotiations are ongoing with government on this recommendation.

Reputational

As part of its Terms of Reference, the inquiry examined the work of THS over a 40-year period. As expected this was set out in its final report.

We will continue to monitor the risks and refer to the board to ensure they are aware of issues arising.

Structure, governance and management

The charity is a company limited by guarantee

The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

37

36

The Haemophilia Society

Annual Report 24/25

Statement of trustee's responsibility

Paul Sartain Rayaz Chel Gordon Dixon Natalie Lawson Conan McIlwrath Amy Owen-Wyard (Resigned September 2025) Clive Smith (Resigned November 2024) Susan Stretch (Resigned January 2025) Jo Traunter Lisa Bagley Stacey McGeown Helen Tate (Appointed November 2024) Peta Dixon (Appointed November 2024) Simon Blackwell (Appointed 7 January 2025)

None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

Auditor

In accordance with the company's articles, a resolution proposing that Ellacotts Audit Services Limited be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The Trustees' report was approved by the Board of Trustees.

..............................

Conan McIlwrath Trustee

Date: 19 December 2025

The Trustees, who are also the directors of The Haemophilia Society for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Independent auditor’s report to the members of the Haemophilia Society

Opinion

We have audited the financial statements of The Haemophilia Society (the ‘charity’) for the year ended 31 March 2025 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

39

38

The Haemophilia Society

Annual Report 24/25

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularites, including fraud

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation

41

40

The Haemophilia Society

Annual Report 24/25

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also performed the following procedures:

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https:// www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Leigh Dudley FCCA (Senior Statutory Auditor)

For and on behalf of Ellacotts Audit Services Limited, Statutory Auditor Chartered Accountants Countrywide House 23 West Bar Banbury Oxfordshire OX16 9SA England

22 December 2025 Date: .........................

Statement of financial activities (including income and expenditure account)

Current financial year

Notes
Income and endowments
from:
Donations and legacies
2
Charitable activities
3
Investments
4
Other income
5
Total income
Expenditure on:
Raising funds
6
Charitable activities
7
Total expenditure
Net gains/(losses) on
investments
12
Net income/(expenditure)
Transfers between funds
Net movement in funds
9
Reconciliation of funds:
Fund balances at 1 April 2024
Fund balances at 31 March
2025		 Unrestricted
funds
2025
£
278,194
140,904
19,128
3,871
442,097
182,318
537,205
719,523
(4,814)
(282,240)
55,767
(226,473)
278,010
51,537		 Restricted
funds
2025
£
142,344
5,835
-
-
148,179
2,886
140,312
143,198
-
4,981
(55,767)
(50,786)
169,666
118,880		 Endowment
funds
2025
£
-
-
-
-
-
-
-
-
-
-
-
-
15,300
15,300		 Total
2025
£
420,538
146,739
19,128
3,871
590,276
185,204
677,517
862,721
(4,814)
(277,259)
-
(277,259)
462,976
185,717		 Total
2024
as restated
£
416,247
106,390
23,473
4,543
550,653
198,337
744,360
942,697
39,212
(352,832)
-
(352,832)
815,808
462,976

All income and expenditure derive from continuing activities. The statement of financial activities includes all gains and losses recognised in the year.

43

42

The Haemophilia Society

Annual Report 24/25

Prior financial year

Balance sheet

Notes
Income and endowments
from:
Donations and legacies
2
Charitable activities
3
Investments
4
Other income
5
Total income
Expenditure on:
Raising funds
6
Charitable activities
7
Total expenditure
Net gains/(losses) on
investments
12
Net income/(expenditure)
Transfer between funds
Net movement in funds
9
Reconciliation of funds:
Fund balances at 1 April 2023
Fund balances at 31 March
2024		 Unrestricted
funds
2024
£
319,950
95,319
23,473
4,324
443,066
184,243
662,133
846,376
39,212
(364,098)
(40,328)
(404,426)
682,436
278,010		 Restricted
funds
2024
£
96,297
11,071
-
219
107,587
14,094
82,227
96,321
-
11,266
40,328
51,594
118,072
169,666		 Endowment
funds
2024
£
-
-
-
-
-
-
-
-
-
-
-
15,300
15,300		 Total
2024
£
416,247
106,390
23,473
4,543
550,653
198,337
744,360
942,697
39,212
(352,832)
-
(352,832)
815,808
462,976

As at 31 March 2025

Notes
Fixed assets
Tangible assets
14
Investments
15
Current assets
Debtors
16
Cash at bank and in hand
Creditors: amounts falling due within one year
17
Net current assets
Total assets less current liabilities
The funds of the charity
Endowment funds
19
Restricted income funds
20
Unrestricted funds
21		 2025
£
49,959
264,993
314,952
(238,481)		 £
44
109,202
109,246
76,471
185,717
15,300
118,880
51,537
185,717		 2024
£
69,694
263,591
333,285
(275,909)		 £
634
404,966
405,600
57,376
462,976
15,300
169,666
278,010
462,976

The financial statements were approved by the Trustees on Friday 19 December 2025.

.............................. Conan McIlwrath Trustee

Company registration number 01763614 (England and Wales)

45

44

The Haemophilia Society

Annual Report 24/25

Statement of cash flows

Notes to the financial statements for the year ended 31 March 2025

Year ended 31 March 2024

Notes
Cash fows from operating activities
Cash absorbed by operations
25
Investing activities
Proceeds from disposal of investments
Investment income received
Net cash generated from investing activities
Net cash generated from fnancing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year		 2025
£
290,950
19,128		 £
(308,676)
310,078
-
1,402
263,591
264,993		 2024
£
364,000
24,473		 £
(264,678)
387,473
-
122,795
140,796
263,591

1 Accounting policies

Charity information

The Haemophilia Society ("THS") is a company limited by guarantee in the United Kingdom. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The address of the registered office is given in the charity information of these financial statements. The nature of the charity's operations and principal activities are to provide support and services to everybody affected by inherited bleeding disorders in the UK.

1.1 Basis of preparation

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Companies Act 2006, the Charities Act 2011 and the provisions of the Charities Act 2022 in force at the time of preparing these accounts, and UK Generally Accepted Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared on a going concern basis under the historical cost convention, modified to include the revaluation of investments at market value. The principal accounting policies adopted are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

1.2 Going concern

At the year end £168,581 (2024 - £157,530) of the total cash and cash equivalents is held on behalf of third parties. An equal and opposite amount is also showing within the other creditor at the year end.

The notes on pages 47 to 62 form part of these financial statements.

The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. Based on the projected cash flow information for 12 months from the date of approval of these financial statements, taking into consideration the estimation of the continued impact of Covid and resources available, the trustees have a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. Thus, the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

THS is represented throughout the country by local groups. Local group funds are incorporated into THS's financial statements.

47

46

The Haemophilia Society

Annual Report 24/25

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds is charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Endowment funds represent those assets which must be held permanently by the charity, principally the Phillip Morris Art Award Fund and the Howard Abraham Memorial Award Fund. The interest earned on these funds is credited to the relevant restricted fund to fund awards.

1.4 Income

All incoming resources are included in the Statement of financial activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

Grant income is recognised in accordance with the terms of the grant and when the conditions of receipt have been complied with. When donors specify that grants given to the charity must be used in future accounting periods, the income is deferred until those periods.

Donations, legacies and similar incoming resources are included in the year in which they are receivable, which is when the charity becomes entitled to the resource.

Income from charitable activities includes income earned from community fundraising and events and local group activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Investment income is earned through holding assets for investment purposes. It includes interest income, which is included when the amount can be measured reliably and the charity's right to receive payment is established.

No amount is included in the financial statements for volunteer time in line with the SORP (FRS 102).

1.5 Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office overheads, governance costs, charity administration and salary core costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at headquarters. Where support costs cannot be directly attributed to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities in proportion to direct costs incurred. Salary costs are allocated based on an analysis of staff time spent.

1.6 Tangible fixed assets

Tangible fixed assets for use by the charity are are initially measured at cost and subsequently measured at cost, less accumulated depreciation.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings 25% per annum, straight line Office equipment and furniture 25% per annum, straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Fixed asset investments

Investments are recognised initially at fair value. Subsequent gains and losses, which represent the difference between the opening market value and closing market value or proceeds of sale, are recognised in the financial statements in the period to which they relate.

1.8 Impairment of fixed assets

Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the asset's cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

VAT is charged as an expense against the activity for which expenditure arose.

49

48

The Haemophilia Society

Annual Report 24/25

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

1.15 Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.16 Taxation

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Pensions in respect of qualifying employees are provided by individual money purchase schemes. THS's contributions to these schemes are charged to the SoFA in year in which they arise.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13 Leases

Rentals payable and receivable under operating leases are charged to the SoFA on a straight line basis over the period of the lease.

1.14 Provisions

Provisions are recognised when the charity has an obligation at the balance sheet date as a result of a past event, it is probable that an outflow of economic benefits will be required in settlement and the amount can be reliably estimated.

The charity is an exempt charity within the meaning of schedule 3 of the Charities Act 2011 and is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes.

2. Income from donations and legacies

U
Donations and gifts
Legacies
Grants and trust income
Corporate income
Other		 nrestricted
funds
2025
£
162,330
69,691
10,500
35,673
-
278,194		 Restricted
funds
2025
£
188
-
12,906
129,250
-
142,344		 Total
2025
U
£
162,518
69,691
23,406
164,923
-
420,538		 nrestricted
funds
2024
£
79,732
181,082
13,387
45,703
46
319,950		 Restricted
funds
2023
£
18,551
-
16,746
61,000
-
96,297		 Total
2023
£
98,283
181,082
30,133
106,703
46
416,247

3. Income from charitable activities

Local group activities
Events
Community fundraising and events
Events		 Unrestricted
funds
2025
£
-
140,904
140,904		 Restricted
funds
2025
£
1,852
3,983
5,835		 Total
2025

£
1,852
144,887
146,739		 Unrestricted
funds
2024
£
-
95,319
95,319		 Restricted
funds
2024
£
794
10,277
11,071		 Total
2024
£
794
105,596
106,390

51

50

The Haemophilia Society

Annual Report 24/25

4. Income from investments

----- Start of picture text -----
Unrestricted Unrestricted
funds funds
2025 2024
£ £
Interest 19,128 23,473
----- End of picture text -----

5. Other incomes

U
Other income
Insurance claim		 nrestricted
funds
2025
£
3,871
-
3,871		 Restricted
funds
2025
£
-
-
-		 Total
2025
U
£
3,871
-
3,871		 nrestricted
funds
2024
Restricted
funds
2024
Total
2024
£
£
£
2,688
219
2,907
1,636
-
1,636
4,324
219
4,543

7. Expenditure on charitable activities

Commu
Direct costs
Activities undertaken directly
Grant funding of activities
Share of support and governance costs
(see note 8)
Support
Analysis by fund
Unrestricted funds
Restricted funds		 nications
2025
Membership
funds
2025
£
£
32,822
6,141
-
-
32,822
6,141
100,369
14,469
133,191
20,610
133,191
20,610
-
-
133,191
20,610		 Services
2025
Advocacy and
infuencing
2025
Cornestone
project
2025
Public
inquiry
2025
Ta
£
£
£
£
67,346
26,645
6,060
(4,997)
-
-
-
-
67,346
26,645
6,060
(4,997)
273,104
35,842
-
75,362
340,450
62,487
6,060
70,365
250,552
62,487
-
70,365
89,898
-
6,060
-
340,450
62,487
6,060
70,365		 nner fund
grants
2025
£
-
44,354
44,354
-
44,354
-
44,354
44,354		 Total
2025
£
134,017
44,345
178,371
499,146
677,517
537,205
140,312
677,517

7. Expenditure on charitable activities (previ ~~ous year)~~

6. Expenditure on raising funds

U
Fundraising and publicity
Seeking donations, grants and legacies
Support costs		 nrestricted
funds
2025
£
49,314
133,004
182,318		 Restricted
funds
2025
£
2,886
-
2,886		 Total
2025
U
£
52,200
133,004
185,204		 nrestricted
funds
2024
Restricted
funds
2024
Total
2024
£
£
£
38,757
14,094
52,851
145,486
-
145,486
184,243
14,094
198,337
Commu
Direct costs
Activities undertaken directly
Grant funding of activities
Share of support and governance costs
(see note 8)
Support
Analysis by fund
Unrestricted funds
Restricted funds		 nications
2024
Membership
funds
2024
£
£
47,351
20,447
-
-
47,351
20,447
109,788
15,827
157,139
36,274
157,139
35,975
-
299
157,139
36,274		 Services
2024
Advocacy and
infuencing
2024
Cornestone
project
2024
Public
inquiry
2024
Tan
£
£
£
£
97,258
21,160
8,365
2,391
-
-
-
-
97,258
21,160
8,365
2,391
298,733
39,206
-
82,434
395,991
60,366
8,365
84,825
315,463
60,366
8,365
84,825
80,528
-
-
-
395,991
60,366
8,365
84,825		 Services
2024
Advocacy and
infuencing
2024
Cornestone
project
2024
Public
inquiry
2024
Tan
£
£
£
£
97,258
21,160
8,365
2,391
-
-
-
-
97,258
21,160
8,365
2,391
298,733
39,206
-
82,434
395,991
60,366
8,365
84,825
315,463
60,366
8,365
84,825
80,528
-
-
-
395,991
60,366
8,365
84,825		 ner fund
grants
2024
£
-
1,400
1,400
-
1,400
-
1,400
1,400		 ner fund
grants
2024
£
-
1,400
1,400
-
1,400
-
1,400
1,400		 Total
2024
£
196,972
1,400
1, 198,372
545,988
1, 744,360
25 400
1, 662,133
82,227
25
-
25		 -
400
400
1, 744,360

53

52

The Haemophilia Society

Annual Report 24/25

8. Support costs allocated to activities

Staff costs
Depreciation
Governance
Travel, postage and carriage
Information technology
Ofce costs
Recruitment, training and temporary staff
Other expenses
Governance costs
Analysed between:
Fundraising
Communications
Membership
Services
Advocacy and infuencing
Public inquiry		 2025
£
473,044
590
24,438
9,105
30,266
21,638
10,571
13,644
48,854
632,150
133,004
100,369
14,469
273,104
35,842
75,362
632,150		 2024
£
511,746
4,537
17,592
25,862
17,718
11,504
11,424
60,745
30,346
691,474
145,486
109,788
15,827
298,733
39,206
82,434
691,474

9. Net movement in funds

2025 2024
£ £
The net movement in funds is stated after charging/(crediting):
Fees payable for the audit of the charity's fnancial statements 10,500 10,500
Depreciation of owned tangible fxed assets 590 2,035
Loss on disposal of tangible fxed assets - 2,502
Operating lease charges 48,854 30,346

10. Trustees

None of the Trustees (or any persons connected with them) received or waived any remuneration or benefits from the charity during the year.

£9,327 (2024 - £7,417) was reimbursed to seven (2024 - eleven) trustees during the year for travel, subsistence and accommodation expenses. Included within trustee expenses was £2,587 (2024 - £2,992) paid directly to third parties.

11. Employees

The average number of employees during the year was:
Employees
Employment costs
Wages and salaries
Social security costs
Other pension costs
The number of employees whose annual remuneration was more than £60,000 is as follows:
£90,001-£100,000
Remuneration of key management personnel
The charity considers its key management personnel to be the board of trustees and the Chief Executive. The
remuneration of key management personnel was as follows:
Aggregate compensation		 2025
Number
10
2025
£
408,984
35,415
28,645
473,044
2025
Number
1
2025
£
103,119		 2024
Number
11
2024
£
443,630
38,517
29,599
511,746
2024
Number
1
2024
£
103,973

12. Gains and losses on investments

Unrestricted Unrestricted
funds funds
2025 2024
Gains/(losses) arising on: £ £
Revaluations of investments (4,814) 39,212

55

54

The Haemophilia Society

Annual Report 24/25

13. Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

14. Tangible fixed assets

Fixtures
Cost
At 1 April 2024
At 31 March 2025
Depreciation and impairment
At 1 April 2024
Depreciation charged in the year
At 31 March 2025
Carrying amount
At 31 March 2025
At 31 March 2024		 and fttings
Ofce equipment and
furniture
£
£
20,169
3,176
20,169
3,176
19,624
3,087
545
45
20,169
3,132
-
44
545
89		 Total
£
23,345
23,345
22,711
590
23,301
44
634

16. Debtors

mounts falling due within one year:
ther debtors
repayments and accrued income		 2025
£
27,250
22,709
49,959		 2024
£
32,098
37,596
69,694

17. Creditors: amounts falling due within one year

Other taxation and social security
Trade creditors
Other creditors
Accruals and deferred income		 2025
£
9,514
30.087
185,625
13,255
238,481		 2024
£
10,562
30,885
169,270
65,192
275,909

The Haemophilia Society has formal partnerships with two organisations that match our mission to support people with bleeding disorders in the UK:

The Haemophilia Nurses' Association (HNA) represents specialist nurses who care for people with bleeding disorders in the UK through direct clinical practice and research.

15. Fixed asset investments

LIsted Investments Cost or valuation £ At 1 April 2024 404,966 Valuation changes (4,814) Disposals (290,950) At 31 March 2025 109,202 Carrying amount At 31 March 2025 109,202 At 31 March 2024 404,966

109,202 404,966

Little Bleeders is a registered charity that supports young people with bleeding disorders by providing grants to participate in sport and physical activities. The Haemophilia Society acts as custodians for both organisations' funds and provides finance and governance expertise. A breakdown of these balances is set out within note 24.

18. Retirement benefit schemes

2025 2024
Defned contribution schemes £ £
Charge to proft or loss in respect of defned contribution schemes 28,645 29,599

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

57

56

The Haemophilia Society

Annual Report 24/25

19. Endowment funds

Endowment funds represent assets which must be held permanently by the charity. Income arising on the endowment funds can be used in accordance with the objects of the charity and is included as unrestricted income. Any capital gains or losses arising on the assets form part of the fund.

Permanent endowments
Previous year
Permanent endowments
Philip Morris Art Award
Howard Abrahams Memorial Award		 At 1 April
2024
£
15,300
At 1 April
2023
£
7,500
7,800
15,300		 At 31 March
2025
£
15,300
At 31 March
2024
£
7,500
7,800
15,300

Philip Morris Art Award: This award is open to students with haemophilia or related bleeding disorders studying the arts. Preference will be given to a student studying music, as a reflection of Philip’s love of music developed in later life.

Howard Abrahams Memorial Award: This is a bursary awarded to an individual with haemophilia or related bleeding disorders in pursuit of one of the professions or study relating to a profession. This award has been made possible by the Abrahams family in memory of their son.

20. Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

At 1 April Incoming Resources Transfers At 31 March
2024 resources expended 2025
£ £ £ £ £
Talking Red 43,392 10,231 (21,458) (23,000) 9,165
Tanner Fund 64 - - - 64
Newly Diagnosed - 31,055 (29,140) (1,915) -
Ambassadors 16,577 10,906 (13,410) - 14,073
Booklets 35,886 4,075 (18,118) (7,000) 14,843
Covid Survey 950 - - (950) -
Youth Camps - 21,103 (29,526) 8,423 -
Centre Engagement 16,705 - (679) - 16,026

20. Restricted funds (continued

Patient Experience Survey
Local Groups
Mental Health Training
EAHAD
Haemfest
Chris Clotter Project
Information Days
WFH Congress
Conference / AGM
Philip Morris Art Award
Howard Abrahams Memorial Award
VWD Event
Previous Year
Talking Red
Tanner Fund
Newly Diagnosed
Ambassadors
Booklets
Covid Survey
Youth Camps
Centre Engagement
Local Groups
Mental Health Training
Haemfest
Community Matters Magazine
Information Days
WFH Congress
Philip Morris Art Award
Howard Abrahams Memorial Award		 At 1 April
2024
£
-
8,859
1,562
-
-
-
1,903
31,705
-
7,971
3,792
30
169,666
At 1 April
2023
£
19,218
64
-
21,000
29,886
950
-
16,706
9,482
1,562
-
-
3,128
4,313
7,971
3,792
118,072		 Incoming
resources
£
6,325
1,852
-
4,000
5,000
12,500
150
10,000
20,795
-
187
10,000
148,179
Incoming
resources
£
30,300
-
15,000
10,000
6,000
-
4,596
-
794
-
5,140
-
-
35,757
-
-
107,587		 Resources
expended
£
-
(2,858)
-
(523)
-
(6,315)
-
(6,060)
(15,111)
-
-
-
(143,198)
Resources
expended
£
(5,828)
-
(22,257)
(14,423)
-
-
(18,141)
-
(1,417)
-
(11,690)
(12,976)
(1,225)
(8,365)
-
-
96,321		 Transfers
£
(6,325)
-
-
-
-
-
-
(25,000)
-
-
-
-
(55,767)
Transfers
£
-
-
7,257
-
-
-
13,545
-
-
-
6,550
12,976
-
-
-
-
40,328		 At 31 March
2025
£
-
7,853
1,562
3,477
5,000
6,185
2,053
10,645
5,684
7,971
3,979
10,300
118,880
At 31 March
2024
£
43,690
64
-
16,577
35,886
950
-
16,706
8,859
1,562
-
-
1,903
31,705
7,971
3,792
169,666

A transfer of £40,328 has been made to reflect costs funded from unrestricted reserves

59

58

The Haemophilia Society

Annual Report 24/25

20. Restricted funds (continued

Talking Red: Talking Red includes all our work for women with bleeding disorders including an awareness campaign and services for those with a diagnosis.

Tanner Fund: A hardship fund providing grants of up to £200.

Memorial Service: Funds held for the administration of an annual service of Thanksgiving and Remembrance in London for those who died as a result of contamination of blood products in the 1970s and 1980s.

THS is represented throughout the country by local groups. Group funds are incorporated into THS's financial statements.

Designated funds - Public inquiry: Recognising the significant financial and general resource impact of the current public inquiry into infected blood, in 2019 the board designated £600,000 of reserves to fund the charity's work on the Inquiry. We participate in the Inquiry and support and inform members of the communicated affected by the Inquiry. Designated funds are reviewed annually and where the duration of the Inquiry is shortened or such amounts of expenditure are not required we will release relevant Designated Funds back in to General Unrestricted Funds.

Designated funds - Liquidation fund: Recognising the impact of Covid on charity income the board has designated funds to provide sufficient cover for approximately months of running costs.

Newly Diagnosed: Fund to support our services and events for families with a newly diagnosed child with a bleeding disorder.

Ambassadors: Fund to support Youth Ambassadors, who are volunteer advocates for the charity, to receive training, attend events and services and support the development of THS’s work and strategy.

Booklets: Funding for productions of information booklets and transition to other languages. Covid Survey: Funding to carry out pre & post Covid survey. Youth Camps – Funding to organise Youth camps to help children and young people to develop independence, by taking part in new experiences and challenges where they will also participate in sessions which focus on learning to self-treat.

Centre Engagement: Funding to help with reengagement with Haemophilia Centres.

Patient Experience: Funding to develop and carry out survey to investigate patient experiences of rare bleeding disorders with the aim of identifying areas in which patients can receive greater support.

Local Groups: Funding to support development and launch of local groups around the UK to support the activities of THS and haemophilia Centres. Mental Health Training: Funding for mental health staff training.

Emergency Fund (Ukraine): Help to provide crucial support to those in need during ongoing conflict and humanitarian crisis in Ukraine.

Haemfest: A camping weekend for families with bleeding disorders.

Community Matters Magazine: formerly titled HQ, the biennial magazine for our members.

Information Days: a series of educational days for Talking Red, Von Willebrand’s Disorder, Rare and bleeding Disorders of Unknown Cause and Haemophilia Live. WFH (World Federation of Haemophilia) Congress: participation at the biennial international congress which in 2022 took place in Montreal, Canada. Cut the Cap: a restricted grant from CSL Behring to create a digital awareness campaign.

Philip Morris Art Award: This award is open to students with haemophilia or related bleeding disorders studying the arts. Preference will be given to a student studying music, as a reflection of Philip's love of music developed in later life.

Howard Abrahams Memorial Award: This is a bursary awarded to an individual with haemophilia or related bleeding disorders in pursuit of one of the professions or study relating to a profession. This award has been made possible by the Abrahams family in memory of their son.

21. Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

Local groups
Designated funds - Public inquiry
Designated funds - Liquidation fund
General funds
Previous year
Local groups
Designated funds - Public inquiry
Designated funds - Liquidation fund
General funds		 At 1 April
2024
£
54,345
78,249
168,733
(23,317)
278,010
At 1 April
2023
£
54,345
78,249
168,733
381,109
682,436		 Incoming
resources
£
-
-
-
442,097
442,097
Incoming
resources
£
-
-
-
443,066
443,066		 Resources
expended
£
-
-
-
(719,523)
(719,523)
Resources
expended
£
-
-
-
(846,376)
(846,376)		 Transfers
£
-
-
-
55,767
55,767
Transfers
£
-
-
(168,732)
(40,328)
(40,328)		 Gains and
losses
£
-
-
-
(4,814)
(4,814)
Gains and
losses
£
-
-
-
39,212
39,212		 At 31 March
2025
£
54,345
78,249
168,733
(249,790)
51,537
At 31 March
2024
£
54,345
78,249
168,733
(23,317)
278,010

22. Analysis of net assets between funds

At 31 March 2025:
Tangible assets
Investments
Current assets/(liabilities)

At 31 March 2024:
Tangible assets
Investments
Current assets/(liabilities)		 Unrestricted
funds
2025
£
44
93,902
(42,409)
51,537
Unrestricted
funds
2024
£
634
389,666
(112,290)
278,010		 Restricted
funds
2025

£
-
-
118,880
118,880
Restricted
funds
2024
as restated

£
-
-
169,666
169,666		 Endowment
funds
2025
£
-
15,300
-
15,300
Endowment
funds
2024
£
-
15,300
-
15,300		 Total
2025
£
44
109,202
76,471
185,717
Total
2024
as restated
£
634
404,966
57,376
462,976

23. Operating lease commitments

Lessee

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Within one year
Between two and fve years		 2025
£
44,220
190,682
234,902		 2024
£
24,649
3,145
27,794

61

60

The Haemophilia Society

Annual Report 24/25

24. Related party transactions

For more information, please visit our website haemophilia.org.uk or contact us on 020 7939 0780 or email info@haemophilia.org.uk

The charity received no donations from trustees during the period (2024: none).

At the year end the charity has the following balances due to other Charities with common trustees: Haemophilia Nurses Association: £101,999 (2024: £88,237) Little Bleeders: £66,581 (2024: £69,293)

25. Cash generated from operations

Defcit for the year
Adjustments for:
Investment income recognised in statement of fnancial activities
(Gain)/loss on disposal of tangible fxed assets
Fair value gains and losses on investments
Depreciation and impairment of tangible fxed assets
Movements in working capital:
Decrease in debtors
Increase in creditors
Cash absorbed by operations		 2025
£
(277,259)
(19,128)
-
4,814
590
19,735
(37,428)
(308,676)		 2024
£
(352,832)
(23,473)
2,502
(39,212)
2,035
2,036
144,266
(264,678)

If you would like this information in a different format, such as audio tape, braille or large print, or in another league , please speak to our team on 020 7939 0708.

Registered charity no. 288260 (Scotland SCO39732)

Company limited by guarantee reg. no. 1763614

Members of the European Haemophilia Consortium and the World Federation of Hemophilia

Chair: Conan McIlwrath Conan@haemophilia.org.uk

President: Clive Smith

26. Analysis of changes in net funds

The charity had no material debt during the year.

63

62

The Haemophilia Society

The Haemophilia Society 52b Borough H gh Street The Haemoph i lia Society London SE1 1XN52b Borough High Street Phone: 020 7939 0780London SE1 1XN Email: info@haemophilia.org.ukPhone: 020 7939 0780 Web: haemophilia.org.ukEmail: info@haemophilia.org.uk

HaemophilaSocietyUK HaemophilaSocietyUK

HaemoSocUK HaemoSocUK

thehaemophiliasociety thehaemophiliasociety

Web: haemophilia.org.uk

© The Haemophila Society 2023

© The Haemophila Society 2023

64